An Epidemiological Update on COVID -19

A Randomized Trial of Hydroxychloroquine as Post-exposure Prophylaxis for COVID-19

Author(s): Kailasam Saravana Mani *

Pp: 55-62 (8)

DOI: 10.2174/9789815050325122010011

* (Excluding Mailing and Handling)


Research revealed that in vitro activity ofchloroquine and the derivative molecule of hydroxychloroquine is against the infection caused by the SARS-CoV and SARS-CoV-2. The US FDA approved the use of both hydroxychloroquinesulfate and chloroquine phosphate for the critical patients of COVID-19. The clinical trials supported that the hydroxychloroquine did not substantially reduce the system severity in non-hospitalized persons. Moreover, it also produces severe side effects like drowsiness, hypokalaemia, nausea, convulsions, shock, and even death.

Keywords: Controlled randomized trial, COVID-19, Hydroxy chloroquine (HCQ), Post exposure prophylaxis, SARS-CoV-2, Therapy.

Related Journals
Related Books
© 2024 Bentham Science Publishers | Privacy Policy